Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $22.33.

A number of equities research analysts have weighed in on NMRA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a report on Wednesday, August 7th. Mizuho began coverage on Neumora Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $20.00 target price on the stock.

Neumora Therapeutics Stock Up 0.2 %

Shares of NMRA stock opened at $11.26 on Monday. The stock’s fifty day moving average price is $10.70 and its two-hundred day moving average price is $12.59. Neumora Therapeutics has a fifty-two week low of $8.33 and a fifty-two week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.37). As a group, analysts forecast that Neumora Therapeutics will post -1.46 earnings per share for the current year.

Institutional Investors Weigh In On Neumora Therapeutics

Hedge funds have recently modified their holdings of the company. Amalgamated Bank acquired a new stake in shares of Neumora Therapeutics during the 4th quarter valued at $29,000. Tower Research Capital LLC TRC bought a new position in Neumora Therapeutics during the 4th quarter worth $44,000. Strs Ohio bought a new position in Neumora Therapeutics during the 4th quarter worth $54,000. SG Americas Securities LLC bought a new position in Neumora Therapeutics during the 4th quarter worth $108,000. Finally, New York State Common Retirement Fund bought a new position in Neumora Therapeutics during the 4th quarter worth $118,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.